Epidemiology of severe acute respiratory illness (SARI) among adults and children aged ≥5 years in a high HIV-prevalence setting, 2009-2012

There are few published studies describing severe acute respiratory illness (SARI) epidemiology amongst older children and adults from high HIV-prevalence settings. We aimed to describe SARI epidemiology amongst individuals aged ≥5 years in South Africa. We conducted prospective surveillance for ind...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 2; p. e0117716
Main Authors Cohen, Cheryl, Walaza, Sibongile, Moyes, Jocelyn, Groome, Michelle, Tempia, Stefano, Pretorius, Marthi, Hellferscee, Orienka, Dawood, Halima, Haffejee, Summaya, Variava, Ebrahim, Kahn, Kathleen, Tshangela, Akhona, von Gottberg, Anne, Wolter, Nicole, Cohen, Adam L, Kgokong, Babatyi, Venter, Marietjie, Madhi, Shabir A
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 23.02.2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:There are few published studies describing severe acute respiratory illness (SARI) epidemiology amongst older children and adults from high HIV-prevalence settings. We aimed to describe SARI epidemiology amongst individuals aged ≥5 years in South Africa. We conducted prospective surveillance for individuals with SARI from 2009-2012. Using polymerase chain reaction, respiratory samples were tested for ten viruses, and blood for pneumococcal DNA. Cumulative annual SARI incidence was estimated at one site with population denominators. We enrolled 7193 individuals, 9% (621/7067) tested positive for influenza and 9% (600/6519) for pneumococcus. HIV-prevalence was 74% (4663/6334). Among HIV-infected individuals with available data, 41% of 2629 were receiving antiretroviral therapy (ART). The annual SARI hospitalisation incidence ranged from 325-617/100,000 population. HIV-infected individuals experienced a 13-19 times greater SARI incidence than HIV-uninfected individuals (p<0.001). On multivariable analysis, compared to HIV-uninfected individuals, HIV-infected individuals were more likely to be receiving tuberculosis treatment (odds ratio (OR):1.7; 95%CI:1.1-2.7), have pneumococcal infection (OR 2.4; 95%CI:1.7-3.3) be hospitalised for >7 days rather than <2 days (OR1.7; 95%CI:1.2-2.2) and had a higher case-fatality ratio (8% vs 5%;OR1.7; 95%CI:1.2-2.3), but were less likely to be infected with influenza (OR 0.6; 95%CI:0.5-0.8). On multivariable analysis, independent risk indicators associated with death included HIV infection (OR 1.8;95%CI:1.3-2.4), increasing age-group, receiving mechanical ventilation (OR 6.5; 95%CI:1.3-32.0) and supplemental-oxygen therapy (OR 2.6; 95%CI:2.1-3.2). The burden of hospitalized SARI amongst individuals aged ≥5 years is high in South Africa. HIV-infected individuals are the most important risk group for SARI hospitalization and mortality in this setting.
Bibliography:Conceived and designed the experiments: CC JM ST MG SAM. Performed the experiments: CC JM ST MG SW MP OH HD SH EV KK AT AvG NW ALC BK MV SAM. Analyzed the data: CC ST AT. Contributed reagents/materials/analysis tools: CC JM ST MG SW MP OH HD SH EV KK AT AvG NW ALC BK MV SAM. Wrote the paper: CC JM ST MG SW MP OH HD SH EV KK AT AvG NW ALC BK MV SAM.
Competing Interests: HD has received honoraria from Novartis and MSD and sponsored travel by Mylan. SAM has received honorarium from GSK, Pfizer, Novartis, Sanofi and MERCK. The other authors do not declare any conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0117716